Correlation between activation of PPARγ and resistin downregulation in a mouse adipocyte cell line by a series of thiazolidinediones

Barnes, 2009, Role of resistin in insulin sensitivity in rodents and humans, Curr. Protein Pept. Sci., 10, 96, 10.2174/138920309787315239 Berger, 2002, The mechanisms of action of PPARs, Annu. Rev. Med., 53, 409, 10.1146/annurev.med.53.082901.104018 Boden, 1997, Role of fatty acids in the pathogenesis of insulin resistance and NIDDM, Diabetes, 46, 3, 10.2337/diab.46.1.3 Boden, 2005, Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients, Diabetes, 54, 880, 10.2337/diabetes.54.3.880 Buckle, 1996, Non-thiazolidinedione antihyperglycaemic agents.1. Alpha-heteroatom substituted beta-phenylpropanoic acids, Bioorg. Med. Chem. Lett., 6, 2121, 10.1016/0960-894X(96)00383-6 Cantello, 1994, [[ω-(Heterocyclylamino) alkoxy] benzyl] -2,4-thiazolidinediones as PotentAntihyperglycemic Agents, J. Med. Chem., 37, 3977, 10.1021/jm00049a017 Chakrabarti, 2002, PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes, Diabetes Obes. Metab., 4, 319, 10.1046/j.1463-1326.2002.00218.x Daquinag, 2011, An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells, Cell Stem Cell., 9, 74, 10.1016/j.stem.2011.05.017 Ferrannini, 1992, The insulin resistance syndrome, Curr. Opin. Nephrol. Hypertens., 1, 291, 10.1097/00041552-199212000-00015 Gijsbers, 2011, Stable reporter cell lines for peroxisome proliferator-activated receptor γ (PPARγ)-mediated modulation of gene expression, Anal. Biochem., 414, 77, 10.1016/j.ab.2011.02.032 Hartman, 2002, Mechanisms regulating adipocyte expression of resistin, J. Biol. Chem., 277, 19754, 10.1074/jbc.M201451200 Haugen, 2001, Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes, FEBS Lett., 507, 105, 10.1016/S0014-5793(01)02968-4 Hussain, 1993, A new approach for measurement of cytotoxicity using colorimetric assay, J. Immunol. Methods, 160, 89, 10.1016/0022-1759(93)90012-V Imran, 2007, Recent thiazolidinediones as antidiabetics, J. Sci. Ind. Res., 66, 99 Lazar, 2007, Resistin – and obesity-associated metabolic diseases, Horm. Metab. Res., 39, 710, 10.1055/s-2007-985897 Lehrke, 2005, The many faces of PPARgamma, Cell, 123, 993, 10.1016/j.cell.2005.11.026 Lohray, 1998, Novel euglycemic and hypolipidemic agents. 1, J. Med. Chem., 41, 1619, 10.1021/jm970444e McTernan, 2002, Increased resistin gene and protein expression in human abdominal adipose tissue, J. Clin. Endocrinol. Metab., 87, 2407, 10.1210/jcem.87.5.8627 McTernan, 2003, Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes, J. Clin. Endocrinol. Metab., 88, 6098, 10.1210/jc.2003-030898 Okuno, 1998, Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats, J. Clin. Invest., 101, 1354, 10.1172/JCI1235 Patel, 2004, Disulfide-dependent multimeric assembly of resistin family hormones, Science, 304, 1154, 10.1126/science.1093466 Patel, 2003, Resistin is expressed in human macrophages and directly regulated by PPAR-γ activators, Biochem. Biophys. Res. Commun., 300, 472, 10.1016/S0006-291X(02)02841-3 Pfaffl, 2001, A new mathematical model for relative quantification in real-time RT-PCR, Nucl. Acids Res., 29, e45, 10.1093/nar/29.9.e45 Rajala, 2003, Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production, J. Clin. Invest., 111, 225, 10.1172/JCI16521 Rajala, 2004, Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting, Diabetes, 53, 1671, 10.2337/diabetes.53.7.1671 Reitman, 2000, Lipoatrophy revisited, Trends Endocrinol. Metab., 11, 410, 10.1016/S1043-2760(00)00309-X Saltiel, 2001, Insulin signalling and the regulation of glucose and lipid metabolism, Nature, 414, 799, 10.1038/414799a Sanchez-Solana, 2012, Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor, Mol. Endocrinol., 26, 110, 10.1210/me.2011-1027 Shimazaki, 2008, Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model, Eur. J. Cancer, 44, 1734, 10.1016/j.ejca.2008.04.016 Steppan, 2001, The hormone resistin links obesity to diabetes, Nature, 409, 307, 10.1038/35053000 Stofkova, 2010, Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity, Endocr. Regul., 44, 25, 10.4149/endo_2010_01_25 Tarcin, 2007, Insulin resistance, adipocyte biology, and thiazolidinediones: a review, Metab. Syndr. Relat. Disord., 5, 103, 10.1089/met.2007.0001 Tarkowski, 2010, Resistin competes with lipopolysaccharide for binding to toll-like receptor 4, J. Cell Mol. Med., 14, 1419, 10.1111/j.1582-4934.2009.00899.x Tontonoz, 2008, Fat and beyond: the diverse biology of PPARgamma, Annu. Rev. Biochem., 77, 289, 10.1146/annurev.biochem.77.061307.091829 Willson, 1996, The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones, J. Med. Chem., 39, 665, 10.1021/jm950395a Yki-Jarvinen, 2004, Thiazolidinediones, N. Engl. J. Med., 351, 1106, 10.1056/NEJMra041001